Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wang, Shuhang ^a   An, Tongtong ^a   Duan, Jianchun ^a   Zhang, Lijian ^a   Wu, Meina ^a   Zhou, Qinghua ^b   Chen, Jinfeng ^a   Zhuo, Minglei ^a   Yang, Lu ^a   Wang, Yuyan ^a   Bai, Hua ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PLATINUM COMPLEX; SCATTER FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHINESE; DRUG EFFICACY; EGFR GENE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATION RATE; ONCOGENE K RAS; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION RATE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84874781893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051021     Document Type: Article

References (35)

1. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-39.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101: 13306-11.
4. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, et al. (2009) A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4: S283.
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or Chemotherapy for Non-Small Cell Lung Cancer with Mutated EGFR. N Engl J Med 362: 2380-8.
6. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-small cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): an open-label, Randomised Phase 3 Trial. Lancet Oncol 11(2): 121-8.
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2: 735-42.
8. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N Eng J Med 361: 958-67.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain. PloSMed 2: 11-14.
10. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 316: 1039-43.
11. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
12. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, et al. (2008) Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clin Cancer Res 14: 6867-76.
13. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, et al. (2012) Influence of Chemotherapy on EGFR Mutation Status for Patients with Non-small Cell Lung Cancer. J. Clin.Oncol. 30: 3077-83.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-16.
15. Bai H, Mao L, Wang HS, Zhao J, Yang L, et al. (2009) Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. J Clin Oncol 27: 2653-59.
16. Wang S, An T, Wang J, Zhao J, Wang Z, et al. (2010) Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 16: 1324-30.
17. Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, et al. (2008) MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 3: 331-9.
18. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-23.
19. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 372: 1809-18.
20. Yatabe Y, Matsuo K, Mitsudomi T, (2011) Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma. Journal of Clinical Oncology 29: 2972-7.
21. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, et al. (2009) Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in nonsmall cell lung cancer. J Thorac Oncol 4: 809-15.
22. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, et al. (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-60.
23. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68: 2106-11.
24. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K, (2008) Intratumor Heterogeneity of EGFR Mutations in Lung Cancer Tissues and its Correlation with the Response to Gefitinib. Cancer science 2008 3: 929-35.
25. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, et al. (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011 29: 3316-21.
26. Sordella R, Bell DW, Haber DA, Settleman J, (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004 305: 1163-7.
27. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010 17: 77-88.
28. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 359: 366-77.
29. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Sci Transl Med. 2011 3: 75ra26.
30. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, et al. (2006) Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clin Cancer Res. 2006 12: 5764-9.
31. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, et al. (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011 17: 1160-8.
32. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The catalogue of somatic mutations in cancer (COSMIC), Curr Protoc Hum Genet 2008; Chapter 10: Unit 10 11.
33. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, et al. (2005) Gefitinib sensitive mutaitons of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res, 2005 11: 4289-94.
34. Dong QG, Han BH, Huang JS, Yang LM, Huang J, et al. (2006) Analysis of EGFR mutation in 176 cases of non-small cell lung cancer. Chin J Oncol, 2006 28: 686-91.
35. Duan JC, An TT, Wu MN, Yang L, Bai H, et al. (2012) Correspondence analysis on EGFR-TKIs′ effect and EGFR mutation in advanced squamous cell lung cancer, Chinese Journal of Tuberculosis and R. 35: 323-8.